PTGX - Protagonist Therapeutics, Inc.
NEXT EARNINGS:
Feb 27, 2026
(in 3 days)
EPS Est: $-0.54
|
Rev Est: $14.9M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$111.75
DETAILS
HIGH:
$117.00
LOW:
$108.00
MEDIAN:
$111.00
CONSENSUS:
$111.75
UPSIDE:
27.88%
Market Cap:
5.46B
Volume:
659,853
Avg Volume:
826,605
52 Week Range:
33.7-96.54
Sector:
Healthcare
Industry:
Biotechnology
Beta:
2.25
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
124
IPO Date:
2016-08-11
EPS (TTM):
4.47
P/E Ratio:
8.64
Revenue (TTM):
434.43M
Total Assets:
744.73M
Total Debt:
10.87M
Cash & Equiv:
97.25M
Rev Growth (5Y):
351.4%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
36.3%
Debt/Equity:
0.02
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-06 | $-0.62 | $-0.59 | -5.1% | $4.7M | $14.9M | -68.4% |
| 2025-08-06 | $-0.55 | $-0.53 | -3.8% | $5.5M | $8.4M | -34.2% |
| 2025-05-06 | $-0.19 | $-0.50 | +62.0% | $28.3M | $6.6M | +332.0% |
| 2025-02-21 | $1.98 | $0.06 | +3200.0% | $170.6M | $81.0M | +110.6% |
| 2024-11-07 | $-0.54 | $-0.59 | +8.5% | $4.7M | $38.8M | -88.0% |
| 2024-08-06 | $-0.50 | $-0.50 | 0.0% | $4.2M | $8.0M | -47.9% |
| 2024-05-07 | $3.26 | $1.19 | +173.9% | $255.0M | $120.0M | +112.5% |
| 2024-02-27 | $0.44 | $0.03 | +1425.1% | $60.0M | $40.0M | +50.0% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 434.43M | 60.00M | 26.58M | 27.36M | 28.63M | 231,000 | 30.93M | 20.06M | 0 | 0 | 0 |
| Net Income | 275.19M | (78.95M) | (127.39M) | (125.55M) | (66.15M) | (77.19M) | (38.92M) | (36.96M) | (37.18M) | (14.86M) | (11.07M) |
| EPS | 4.47 | -1.39 | -2.52 | -2.65 | -1.92 | -2.98 | -1.74 | -2.09 | -5.72 | -2.52 | -1.88 |
| Total Assets | 744.73M | 357.95M | 247.93M | 347.69M | 324.47M | 154.92M | 139.47M | 163.73M | 93.99M | 14.85M | 10.33M |
| Total Debt | 10.87M | 1.14M | 3.66M | 5.86M | 5.96M | 17.01M | 0 | 0 | 0 | 0 | 0 |
| Cash & Equivalents | 97.25M | 186.73M | 125.74M | 123.67M | 117.36M | 33.01M | 82.23M | 106.03M | 21.08M | 4.05M | 9.32M |
| Operating Cash Flow | 184.15M | (70.24M) | (108.14M) | (107.86M) | (72.48M) | (41.53M) | (49.95M) | 3.87M | (29.97M) | (14.38M) | (7.74M) |
| Free Cash Flow | 182.80M | (70.84M) | (108.93M) | (108.97M) | (72.95M) | (42.49M) | (50.43M) | 3.21M | (30.35M) | (14.78M) | (8.04M) |
| FCF per Share | 2.97 | -1.25 | -2.22 | -2.35 | -2.12 | -1.64 | -2.26 | 0.18 | -4.67 | -2.51 | -1.37 |
| Book Value | 675.29M | 336.68M | 215.61M | 300.02M | 279.61M | 79.96M | (140.47M) | (101.55M) | (64.59M) | 9.60M | 7.96M |
| Cash & ST Investments | 418.91M | 341.62M | 237.35M | 326.90M | 305.81M | 133.02M | 128.85M | 144.00M | 77.60M | 11.92M | 9.32M |
| ROC Equity | 0.41 | -0.23 | -0.59 | -0.42 | -0.24 | -0.97 | N/A | N/A | N/A | -1.55 | -1.39 |